Menu
ncarol.com
  • Home
  • Education
  • Health
  • Books
  • Technology
  • Real Estate
  • Entertainment
  • Music
  • Business
ncarol.com

Juventix Regenerative Medical PRP Highlighted in University-Published Research Study
ncarol.com/10280466

Trending...
  • CCHR Report Links 145 Violent Incidents to Psychiatric Drug Exposure, Urges National Oversight and Action
  • Outlier Pest Season Hits Willamette Valley as Mild Winter Drives Early Surge in Ant and Rodent Activity
  • $10 Million Annual Revenue Merger, Profitable Partner in AI Powered Specialty Automotive Sales Projected to Scale Above $200M: Stock Symbol: NWPG
Laboratory Testing for Product Validation BSR Labs Juventix PRP Study Table Juventix Packaging With Tubes Juventix Regenerative Medical, LLC
TAMPA, Fla. - ncarol.com -- Juventix Regenerative Medical, a leader in regenerative medicine solutions, proudly announces that its Platelet-Rich Plasma (PRP) technology has been featured in a groundbreaking university-published research study. The study, titled "Platelet-Rich Plasma for Rheumatoid Arthritis: A Case Series", published in the peer-reviewed journal Cureus, underscores the efficacy of Juventix PRP in managing rheumatoid arthritis, showcasing its transformative potential in clinical applications.

The study explores the use of PRP to address inflammation and improve outcomes in rheumatoid arthritis patients, with findings demonstrating measurable benefits attributed to Juventix PRP's advanced process. The research highlights the role of PRP in promoting tissue repair and reducing joint pain, offering a promising non-surgical alternative for patients seeking regenerative therapies.

Scientific Validation Backed by Laboratory Studies
Juventix PRP's inclusion in this research aligns with findings from extensive laboratory evaluations conducted by BioSciences Research Associates (2020) and Biofyl Scientific Research (2023). Key results include:
  • 84% platelet recovery, significantly enhancing platelet-derived growth factor (PDGF) concentrations.
  • 10x increase in PDGF levels, with treated PRP reaching 10,844 pg/mL compared to 1,536 pg/mL in untreated samples.
  • Minimal contamination of red and white blood cells, ensuring safety and reducing inflammatory risks.
  • Optimized pH of 7.5, creating an ideal environment for platelet activation and growth factor release.
  • Innovative activation methods, including photoactivation and bio-incubation, transforming PRP into PRF for versatile clinical applications.
"The inclusion of Juventix PRP in a peer-reviewed study underscores our commitment to delivering scientifically validated, high-quality regenerative solutions," said Lance Liberti, CEO of Juventix Regenerative Medical. "Our focus on innovation ensures practitioners can trust Juventix PRP for consistent, superior patient outcomes."

More on ncarol.com
  • 62% of Gen X have no estate planning documents — Trust & Will research identifies "the Sandwich Gap"
  • Nayarit's Jungle Coast Redefines Luxury Travel on Mexico's Pacific Now More Accessible Than Ever
  • $10 Million Annual Revenue Merger, Profitable Partner in AI Powered Specialty Automotive Sales Projected to Scale Above $200M: Stock Symbol: NWPG
  • Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
  • Crankshooter Names Christian DiMonda Director of Marketing to Lead Brand Growth & Community Strategy

Special Offer for Medical Practitioners
To introduce clinicians to its cutting-edge PRP systems, Juventix is offering a sample PRP kit for only $20. This limited-time opportunity enables practitioners to experience the proven quality of Juventix PRP firsthand.
• Email: hello@juventix.com with the subject line "SAMPLE"
• Visit: https://juventix.com/sample-page/

About Juventix Regenerative Medical, LLC
Founded in 2017 by Lance Liberti, Juventix Regenerative Medical has been a pioneer in non-surgical regenerative solutions, including FDA-cleared PRP kits. The company offers comprehensive products such as centrifuges, LED activators, and bio-incubators to support superior PRP preparation. Juventix also collaborates with prestigious organizations, including the University of South Florida (USF) Health Center for Advanced Medical Learning and Simulation (CAMLS), to host advanced clinical training symposiums.

For more information, visit www.Juventix.com or contact:
📞 (866) 693-4777

More on ncarol.com
  • RAS AP Consulting Launches Vendor Master File & Payment Controls Assessment for NACHA Phase 2 Compliance
  • Living Waters Inc Announces the Passing of Founder and Former President & CEO Lawrence Barker-Bey, Jr
  • New Homesites Released at Heritage at Manalapan Featuring Scenic Golf Course Views
  • The Ultimate Solution to Halt Thermal Runaway
  • Strategic Talent Associates Launches THE ALIGNED RESET™

✉️ Email:
hello@juventix.com
Restore, Revive, Regenerate – Juventix Regenerative Medical.

Media Contact
Lance Liberti
***@juventix.com
866-693-4777


Source: Juventix Regenerative Medical, LLC
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Hazel E Celebrates Birthday with Luxury "Goddess" Yacht Experience in Marina del Rey
  • SoPi Rugby's Taco Cook-Off (Cinco de Mayo Weekend)
  • Joseph Neibich sits down with Bold Jounrey (aka Joseph Nybyk)
  • Healing Hearts Home Care Hosts Peace of Mind Community Event
  • AI Suite 360 Launches Done-For-You AI Implementation to Rescue SMBs from the "Frankenstein Tax"
  • CX Network Releases Report on the Best AI Support Tools for SaaS Companies 2026
  • Outlier Pest Season Hits Willamette Valley as Mild Winter Drives Early Surge in Ant and Rodent Activity
  • Hinton Called for Maternal Instincts in AI; They're Ready for Testing with Anthropic's Mythos
  • Lokal Media House Wins Web Excellence Award for Black Plumbing Redesign
  • Charlotte Founder Launches Foot Odor Brand After Years of Embarrassment
  • Lick Expands Flavored Massage Oil Collection with 10 New Indulgent Cream-Inspired Scents
  • New from Regal House Publishing, Local Heroes, Lyric poems exploring themes drawn from ordinary life
  • New Research Identifies "Vacation Compatibility Gap" as the Hidden Force Shrinking How Long and With Whom Americans Travel
  • Melospeech Inc. Awarded New NYSDOH BEI Contract in New York
  • Five-star Review for Berklee School of Music Textbook
  • ZionSphere Launches Multi-Platform Virtual Reality Faith Experience Built from Rocky Mount, NC
  • Rocky Mount Founder Builds Virtual Reality Bible Experiences After Receiving Divine Directive
  • Advanced TeleSensors Appoints AgeTech Innovator Tiffany Wey, MBA as Vice President of Sales & Marketing
  • Daniel Kaufman Real Estate Venture LoneStar Kaufman Development Partners Expands
  • Brian D Chase Selected to the 2026 Nation's Top One Percent Personal Injury Lawyers
_catLbl0 _catLbl1

Popular on ncarol.com

  • UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis - 112
  • Sycor Introduces Spring Release 2026 of Sycor.Rental with AI-Driven Innovations and Enhanced Service Processes
  • Advanced TeleSensors Appoints AgeTech Innovator Tiffany Wey, MBA as Vice President of Sales & Marketing
  • Pacific Emblem Company Launches "Happy 250th Birthday America" Collection and Proud Supporter of the Gary Sinise Foundation
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
  • Bold Beauty Project Celebrates Anniversary with Collaborative Exhibition at FIU's Miami Beach Urban Studios
  • PlanetAI Nature Space (PNS), certificadora Europea, lanza su plataforma EUDR-PNS Ready basada en IA, satélites y trazabilidad blockchain
  • Most Americans Choose Their Water Brand Because of Its Natural Source — Yet Fewer Than 3 in 10 Understand What Spring Water Actually Is
  • $112 Million Contract Backlog for Cycurion (N A S D A Q: CYCU) Enters Hyper-Growth Phase With, Strategic Acquisitions, & Exploding AI Cybersecurity
  • Special Alert! Highly Undervalued Stock: $317M Revenue in 2025 for Telecom Leader IQSTEL, Inc. (N A S D A Q: IQST)

Similar on ncarol.com

  • Why Athletic Recovery Begins in the Nervous System
  • Strategic Talent Associates Launches THE ALIGNED RESET™
  • Karen D. Gentry Announces New Book Focused on Relationships and Personal Growth
  • New plusOne Research Finds the Orgasm Gap Is a 30-Point Chasm — and Confirms It Isn't Biology
  • CCHR Report Links 145 Violent Incidents to Psychiatric Drug Exposure, Urges National Oversight and Action
  • Healing Hearts Home Care Hosts Peace of Mind Community Event
  • CX Network Releases Report on the Best AI Support Tools for SaaS Companies 2026
  • Charlotte Founder Launches Foot Odor Brand After Years of Embarrassment
  • Lick Expands Flavored Massage Oil Collection with 10 New Indulgent Cream-Inspired Scents
  • Advanced TeleSensors Appoints AgeTech Innovator Tiffany Wey, MBA as Vice President of Sales & Marketing
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute